Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily. The TNF/TNF receptor superfamilies comprise more than a dozen proteins that play a crucial role in the regulation of the immune response, making them attractive immunotherapy targets.
Our most advanced immunotherapy candidate asunercept is being developed for the treatment of solid tumors, malignant hematological diseases, and viral infections, such as COVID-19. It has delivered outstanding results in clinical trials in glioblastoma (GB) and myelodysplastic syndromes (MDS) to date. Asunercept was granted orphan drug status for the treatment of glioma and MDS in the EU and for the treatment of GB and MDS in the US. It has also been awarded PRIME designation by the European Medicines Agency (EMA) for the treatment of GB.
Given the urgent need for COVID-19 treatments, Apogenix has evaluated asunercept in a phase II trial in COVID-19 patients in Spain and Russia. There is a strong scientific rationale of using asunercept to block CD95L-mediated epithelial lung damage and a high interest from international key opinion leaders.
For more information regarding partnering opportunities, please contact:
Patrick Fuchs, Ph.D.
VP Business and Corporate Development
Phone: +49 (0) 6221 586080